GlassScriptPhysician profile
James Ashford
NPI 1447693833
$4,505.23
in general payments reported to CMS, 2019-2025
22 companies · $453 in 2025
The $453 reported for 2025 was less than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $457 · 2020: $858 · 2021: $711 · 2022: $880 · 2023: $572 · 2024: $574 · 2025: $453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,599.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,599.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $1,010.87 | 2020-2025 | Ztlido |
| Horizon Therapeutics Plc | $630.61 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $434.83 | 2019-2025 | Belbuca |
| Forte Bio-Pharma LLC | $350.14 | 2020-2025 | Prolate, Nalocet, Tanlor |
| Biodelivery Sciences International, INC. | $307.51 | 2019-2021 | |
| Boston Scientific Corporation | $292.08 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $239.24 | 2020-2025 | Relistor |
| Nevro Corp. | $214.45 | 2020 | |
| Wound Management Technologies, INC | $180.54 | 2019 | |
| Curonix LLC | $156.69 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Merck Sharp & Dohme LLC | $115.23 | 2020-2023 | Belsomra |
| Spr Therapeutics, INC | $102.58 | 2025 | Sprint Pns System |
| Abbott Laboratories | $88.92 | 2019-2024 | Proclaim |
| Painteq LLC | $71.82 | 2023-2024 | Painteq |
| Vertex Pharmaceuticals Incorporated | $68.03 | 2024-2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Globus Medical, INC. | $47.33 | 2025 | Senza |
| Ibsa Pharma INC. | $38.34 | 2020-2023 | Tirosint, Licart |
| Virtus Pharmaceuticals LLC | $37.44 | 2025 | Levorphanol Tartrate |
| Pfizer INC. | $36.19 | 2019-2023 | |
| Abbvie INC. | $34.58 | 2021-2022 | |
| Grt US Holding, INC. | $32.47 | 2021 | |
| Vertos Medical, INC. | $15.34 | 2023 | Mild Device Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Ashford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.